Scotiabank initiated coverage of Legend Biotech with a Sector Perform rating and $65 price target. The firm believes Legend’s share price fully values the high potential of Carvykti in multiple myeloma and gross margin improvements following the “relatively near-term” completion of CAR-T manufacturing facilities, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LEGN:
- Legend Biotech reports outcomes in CARTITUDE-4 study of CARVYKTI
- Citi opens ‘positive catalyst watch’ on Legend Biotech
- There’s an Opportunity Brewing in These 3 Stocks, Says Goldman Sachs
- Cabaletta Bio, Gracell slide as FDA probes risk of CAR T cell immunotherapies
- FDA probing risk of T-cell malignancy following CAR T cell immunotherapies
